Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2021-09-02 00:00:00 ET · period of report 2021-09-01 · accession 0001209191-21-054542 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-02 | 2021-09-01+ | RARE | Bedrosian Camille L | EVP, Chief Medical Off | M - OptEx | $55.00 | +5,000 | 41.3K | +14% | +$275.0K |
| DM | 2021-09-02 | 2021-09-01+ | RARE | Bedrosian Camille L | EVP, Chief Medical Off | S - Sale+OE | $100.11 | -5,000 | 38.8K | -11% | -$500.5K |
| DM | 2021-09-02 | 2021-09-01+ | RARE | Bedrosian Camille L | EVP, Chief Medical Off | M - OptEx | $0.00 | -5,000 | 53.0K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-01 | M | A | 2,500 | $55.00 | 41,275 | D | — | — | |
| 2 | Common | Common Stock | 2021-09-01 | S | D | 2,500 | $100.03 | 38,775 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2021-09-02 | M | A | 2,500 | $55.00 | 41,275 | D | — | — | |
| 4 | Common | Common Stock | 2021-09-02 | S | D | 2,500 | $100.18 | 38,775 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Derivative | Stock Option (Right to Buy) | 2021-09-01 | M | D | 2,500 | $0.00 | 55,500 | D | $55.00 · — to 2028-01-30 | 2,500 Common Stock | (F4) The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2021-09-02 | M | D | 2,500 | $0.00 | 53,000 | D | $55.00 · — to 2028-01-30 | 2,500 Common Stock | (F4) The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date. |